Related Experiment Videos
[Lercanidipine, a third generation calcium antagonist. Which advantages?].
1Service de néphrologie et Consultation d'hypertension, CHUV, 1011 Lausanne. pascal.meier@chuv.ch
Revue Medicale Suisse
|October 6, 2006
Summary
Lercanidipine, a third-generation dihydropyridine, offers effective blood pressure control with improved tolerability compared to other antihypertensives. It presents a favorable safety profile, reducing side effects like reflex tachycardia and peripheral edema.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Background:
- Lercanidipine is a third-generation dihydropyridine calcium channel blocker.
- It is characterized by high lipophilicity and a vasodilatory mechanism of action.
Purpose of the Study:
- To evaluate the efficacy and tolerability profile of lercanidipine.
- To compare lercanidipine with other antihypertensive agents.
Main Methods:
- Comparative therapeutic trials were conducted.
- Efficacy and adverse events were assessed.
Main Results:
- Lercanidipine demonstrated equal efficacy to other dihydropyridines, beta-blockers, and ACE inhibitors.
- It exhibited an improved tolerability profile with fewer adverse events.
- Common side effects included headache and flushing, primarily related to vasodilation.
- Lercanidipine showed reduced incidence of reflex tachycardia and peripheral edema.
Conclusions:
- Lercanidipine is a well-tolerated antihypertensive agent.
- Its favorable safety and efficacy profile supports its use in diverse patient populations.
- Lercanidipine offers potential for improved blood pressure management, especially in patients intolerant to other agents.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...